Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.
Trial Parameters
Brief Summary
Belatacept inhibits T cell activation by blocking the costimulatory signal. In kidney transplantation, it limits the use of anticalcineurins while ensuring a satisfactory level of immunosuppression.
Eligibility Criteria
Inclusion Criteria: * Renal transplant follow-up at Rouen University Hospital * Clinico-biological intolerance to anticalcineurins defined by GFR \< 25 mL/min and/or water and sodium overload justifying the prescription of loop diuretics and/or post-transplant diabetes and/or resistant hypertension (requiring at least 3 treatments antihypertensives including a thiazide diuretic to reach an objective ≤ 140/90 mmHg). * Having performed a graft biopsy \< 3 months old finding lesions of fibrous endarteritis ≥ 2 or arteriolar hyalinosis ≥ 2 * Having undergone collegial validation for the initiation of treatment with belatacept combined with 3-month anti-CMV prophylaxis with oral Valganciclovir. * Absence of contraindication to belatacept * Patient who has never received belatacept * Having a positive CMV serological status Exclusion Criteria: * Patient with symptomatic infection * Pregnant or parturient or breast-feeding woman or lack of proven effective contraception * Person deprived of l